|
The customer reported a false positive reaction during patient antibody screening when a sample was tested in the same batch as another sample from a patient receiving anti-cd38 therapy.- additional information: the customer confirmed that sample (b)(6) belongs to the patient with anti-cd38.- daily journal review: the sample showed in antibody screening test strong reactions interpreted 1+.The other sample (b)(6) showed in antibody screening test weaker reactions interpreted 1+ as well.- traces files analysis: review of the complete workflow shows that the pipetting needle sequentially accessed tubes (b)(6), then again (b)(6), followed by (b)(6).Given this sequence, there is a credible risk of carry-] over.Specifically, sample (b)(6) may have been contaminated during the antibody screening process after the needle previously aspirated material from sample (b)(6) during the forward grouping test.This sequence constitutes a plausible technical explanation for the observed findings and should be considered a likely contributing factor in the investigation.Resolution: there is the "faq anti-cd38 samples testing on instruments" document available in the ih-area.It provides explanation and advice regarding the handling of samples from patients having anti-cd38 treatment.
|